This legislation is expected to create more demand for GATC’s drug discovery and development platform as artificial intelligence and machine learning are increasingly used to advance drug discovery for human trials
IRVINE, California, 25 January 2023 /PRNewswire/ — GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), announced today that the FDA Modernization Act 2.0 was signed into law in December 2022, ends an FDA mandate that experimental drugs must be tested on animals before being used on humans in clinical trials. The new legislation allows new technologies, including GATC’s computer modeling that predicts potential drug safety and efficacy in humans, to be used to advance drug trials for human trials without animal testing requirements.
In 1938, Congress passed the US Federal Food, Drug and Cosmetic Act, which mandated animal toxicity testing. Since then, science and data have shown that animal studies are highly inconsistent in predicting toxic reactions in humans. More than nine out of 10 drugs that enter FDA human trials fail and do not make it to market because they are unsafe or ineffective. The new FDA Modernization Act 2.0 stipulates that new drug candidates will no longer have to undergo animal testing before beginning human trials and signals a major shift toward computer modeling as the preferred method for simulating the safety and efficacy of new compounds in humans prior to drug development is approved by the FDA.
Artificial intelligence reached its “AlphaGo” moment for pharma in 2018, according to Deep Pharma Intelligence, with validating breakthroughs from IBM Watson, Insilico, Healx and DeepMind occurring in the same year. GATC Health’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform is mature, in production and ahead of the curve. MAT surpasses current AI for drug discovery by simulating the billions of interactions of human biochemistry for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC’s computer simulation models use human biological components to more accurately predict medical and biological outcomes than animal studies. In a triple-blind retrospective study analyzing 14,000 known compounds, MAT accurately identified drug candidates that would have a beneficial effect on human biology with 88% accuracy, while detecting errors with 84% accuracy. GATC is currently in advanced preclinical trials with new compounds that were discovered and modeled using GATC’s MAT platform.
“It is important to realize that although an animal’s biological components may resemble their human counterparts, they are not identical. These subtle differences can result in erroneous interpretations,” says Dr. jonathan lakeyprofessor emeritus in surgery and biomedical engineering University of California Irvine and GATC Health Advisor. “We believe that GATC’s computer modeling can more quickly and accurately predict physiological response to new compounds better than animal testing, potentially saving years, costs and lives.”
GATC Health’s advanced AI platform reduces risk, time and cost by developing more effective drugs and treatments. GATC can analyze a huge amount of disease-specific data with an AI solution that understands the core biology of a disease and can mimic a human environment for discovering and validating new drugs. The company’s MAT platform can analyze 400 trillion biological data points in seven minutes and simulate biochemical interactions to accurately predict a pharmaceutical asset’s response to a specific disease. Through fast and accurate simulation, the MAT platform can develop 1-3 new drug candidates in 3-6 months with the ability to support end-to-end services across research and development.
About GATC Health
GATC Health Corp is a science and technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates the billions of interactions of human biochemistry for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC envisions the future of medicine now, where health is protected, disease is reversed, and each person’s unique biology is treated with precision.
GATC is accelerating the future of predictive, individualized medicine today.
SOURCE GATC Health Corp